This session explores the management of patients who present with new atrial fibrillation shortly after its initiation. A joint session with World Society of Arrhythmias.

• Define "new" or "recent onset" atrial fibrillation and describe how it presents.
• Describe the influence of underlying cardiovascular disease on the progression of the arrhythmia.
• Summarize the effect of atrial fibrillation on prognosis in patients where atrial fibrillation may aggravate or precipitate cardiovascular disease.

Ali Oto, MD
Tristram Bahnson, MD

Recent Onset AF: Can We Define Recent?
Presenter(s): Benjamin A. Steinberg, MD, MHS

Early Initiation of Rhythm Control in AF and Associated Outcomes including Atrial Fibrillation Recurrence and Major Adverse Cardiovascular Events
Presenter(s): Bulent Gorenek, MD

Age and the Utilization of Rhythm Control Strategies for Early Onset AF
Presenter(s): Thorsten Lewalter

Best ‘First Line’ Rhythm-Control Approach: Ablate It Away or Suppress It with Drugs?
Presenter(s): Jose F. Huizar, MD

Benjamin Steinberg:

• AltaThera Pharmaceuticals (Research (Contracted Grants for PIs and Named Investigators only) - Research)
• Milestone Pharmaceuticals (DSMB - Membership on Advisory Committees or Review Panels)
• Bayer Healthcare Pharmaceuticals (Consulting - Consulting)
• Boston Scientific (Research (Contracted Grants for PIs and Named Investigators only) - Research)
• Cardiva Medical, Inc. (Research (Contracted Grants for PIs and Named Investigators only) - Research)
• Sanofi (Research (Contracted Grants for PIs and Named Investigators only) - Consulting)
• Element Science, Inc (DSMB - Consulting)
• Bayer Healthcare Pharmaceuticals (Honoraria/Speaking/Consulting Fee - Consulting)

Bulent Gorenek:

• Nothing Relevant to Disclose

Thorsten Lewalter:

• Biotronik (Speakers' Bureau - Board Membership)
• Medtronic,Inc. (Honoraria/Speaking/Consulting Fee - Board Membership)
• Daiichi Sankyo (Honoraria/Speaking/Consulting Fee - Speaking and Teaching)
• Boston Scientific (Honoraria/Speaking/Consulting Fee - Speaking and Teaching)
• Bayer Healthcare Pharmaceuticals (Honoraria/Speaking/Consulting Fee - Speaking and Teaching)
• Abiomed (Honoraria/Speaking/Consulting Fee - Speaking and Teaching)
• Pfizer/BMS (Honoraria/Speaking/Consulting Fee - Speaking and Teaching)

Jose Huizar:

• Abbott (Research (Contracted Grants for PIs and Named Investigators only) - Research)

To view all Heart Rhythm 2025 Faculty Disclosures, please click here.

Supraventricular Tachyarrhythmias
   --   AFib and Flutter
      --   110. Know the various clinical presentations of atrial fibrillation and flutter, including tachycardia-mediated cardiomyopathy.

Supraventricular Tachyarrhythmias
   --   AFib and Flutter
      --   113. Know the role and limitations of screening populations for asymptomatic atrial fibrillation and flutter for stroke prevention.

Supraventricular Tachyarrhythmias
   --   AFib and Flutter
      --   114. Know the influences of modifiable risk factors such as obesity, sleep apnea, hypertension and cardiovascular fitness on AF and indications for referring patients for additional testing and treatment.